US EditionPublished • loading... • Updated
Enanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC Wainwright
Summary by defenseworld.net
1 Articles
1 Articles
Enanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock. A number of other brokerages also recently commented on ENTA. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight”…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
